Sensei Bio

16 articles about Sensei Bio

• Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

  9/27/2023

  Sensei Biotherapeutics, Inc. today announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

• Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

  9/21/2023

  Sensei Biotherapeutics, Inc. today will present new preclinical data from SNS-101, a clinical-stage conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference.

• Sensei Biotherapeutics to Participate in Upcoming September 2023 Investor Conferences

  8/30/2023

  Sensei Biotherapeutics, Inc., a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, announced that Company management will participate in the following investor conferences in September 2023.

• Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

  8/3/2023

  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.

• Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

  8/2/2023

  Sensei Biotherapeutics, Inc. today announced that Company management will participate in a fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference, being held in Boston, MA, on Wednesday, August 9, 2023 at 9:30 a.m. ET.

• Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”

  6/13/2023

  Sensei Biotherapeutics, Inc. announced that the Company will host a virtual KOL event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors,” on Tuesday, June 27, 2023 at 2:00 p.m.

• Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

  6/1/2023

  Sensei Biotherapeutics, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating SNS-101 for the treatment of advanced solid tumors.

• Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

  5/9/2023

  Sensei Biotherapeutics today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.

• Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

  4/20/2023

  Sensei Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, paving the way for the Company to conduct a Phase 1/2 clinical trial in patients with solid tumors.

• Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

  4/13/2023

  Sensei Biotherapeutics, Inc. today announced that Company management will participate in a panel titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Thursday, April 20th at 3:00 p.m. ET.

• Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

  3/28/2023

  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for full-year 2022 and provided recent business updates.

• Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

  3/21/2023

  Sensei Biotherapeutics, Inc. today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, in patients with solid tumors.

• Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

  3/14/2023

  Sensei Biotherapeutics, Inc. will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 at the American Association for Cancer Research Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL.

• Sensei Biotherapeutics Adopts Stockholder Rights Agreement

  3/7/2023

  Sensei Biotherapeutics, Inc. today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests and maximize value for all stockholders.

• Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

  3/6/2023

  Sensei Biotherapeutics, Inc. today announced that Company management will present at Oppenheimer’s 33rd Annual Healthcare Conference.

• Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101

  1/5/2023

  Sensei Biotherapeutics, Inc. today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo ®  (cemiplimab).